CARMAT's Aeson® Artificial Heart: Promising Results for Heart Failure with Pulmonary Hypertension

CARMAT's Aeson® total artificial heart has shown encouraging results for heart failure patients suffering from pulmonary hypertension. As published in The Journal of Heart and Lung Transplantation, a study conducted at the University Medical Center of Astana highlighted Aeson®'s ability to provide real-time monitoring, improving patient outcomes.

In a single-center study involving three patients, the Aeson® implant improved functional capacity and enabled hospital discharge within 68, 48, and 48 days. The device's innovative features, including its ability to estimate transpulmonic resistance, made heart transplant possible for these patients.

The findings underscore the challenges faced by up to 25% of advanced heart failure patients with pulmonary hypertension. Aeson® offers balanced biventricular support, potentially serving as a bridge-to-transplant or a definitive therapy, addressing the needs of a difficult-to-treat population.